Actively Recruiting
Evaluation of INV-8989 Safety, Drug Behavior, and Early Anti-Cancer Effects in Adults with KRAS G12D Mutated Advanced Solid Tumors
Led by Shenzhen Ionova Life Sciences Co., Ltd. · Updated on 2026-06-10
178
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety, tolerability, how the body processes the drug, and early anti-cancer effects of INV-8989 in adults with advanced solid tumors that have KRAS G12D mutations. The study is divided into Phase 1 and Phase 2 parts Phase 1 focuses on finding the right dose and assessing safety, while Phase 2 expands to more patients and explores different tumor types with this mutation, especially those who have not responded to standard treatments. Participants receive INV-8989 once a week. In Phase 1, doses are gradually increased to monitor safety and determine the recommended dose. Phase 2a further confirms safety, drug behavior, and preliminary effectiveness, optimizing the dose. Phase 2b then explores anti-tumor effects in different patient groups with KRAS G12D mutated tumors who have failed previous treatments. Throughout the study, participants will be regularly monitored for side effects, drug levels in the body, and tumor response using standard criteria. Researchers will track adverse events and measure overall response rates and progression-free survival over 12 months. The study also requires tumor tissue samples either from archives or new biopsies. Participation lasts through the treatment and assessment periods until study completion.
CONDITIONS
Brief Title
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-8989 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutations
Research Team
Y
Yi Zhu, MD, MBA
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here